Slide 1: Report Q2 2025
Report Q2 2025 July 18, 2025 Cecilia de Leeuw Linda Frölén CEO CFO
Slide 2: Q2 2025 – Key takeaways
Q2 2025 – Key takeaways Taking steps towards our financial targets Order Intake YoY: High market activity and building momentum Growing order intake 11%* - Driven by Americas and EMEA regions Revenue YoY: Strong order backlog of 735 MSEK -13%* Weaker topline in the quarter - Strong comparison with Q
Slide 3: Q2 development by region
-15% Q2 development by region Order Intake +47% 68 58 +11% 46 AMERICAS – Larger US orders despite market uncertainty 31 31 28 - Product order (10 MSEK) to prominent Texas Cancer Centre - Multiple Service contract renewals, incl US East Coast order EMEA – Continued momentum and signs of recovery Amer
Slide 4: Q2 Financials
Q2 Financials Linda Frölén, CFO
Slide 5: Q2 Financials
Q2 Financials Order Intake Revenue Gross Profit Gross Margin 134.8 (127.4) MSEK 105.2 (129.4) MSEK 70.2 (87.9) MSEK 67 (68) % +6% -19% -20% -127 bips OPEX EBIT EBIT Margin Operating Cash Flow 61.0 (68.0) MSEK 8.4 (18.1) MSEK 8 (14) % 0.5 (-2.6) MSEK -12% -54%
Slide 6: Stable Gross Margin in the mid-60s
Stable Gross Margin in the mid-60s Gross profit & Gross margin by quarter Gross profit Q2’25: 100,0 74% 70.2 (88.0) MSEK. 90,0 72% Decrease Y/Y following lower revenue, partly 80,0 70% offset by contribution from service revenue. 70,0 68% 60,0 Gross margin Q2’25: 50,0 66% 67 (68) %. 40,0 64% Gross m
Slide 7: Continued improved cost control
Continued improved cost control Y/Y Q/Q Development Y/Y: -7.0 MSEK -10% 68,0 +9% Higher personnel expenses and 61,0 61,0 lower expenses for external 56,1 consultants as consultants has been replaced with own staff. Development Q/Q: +4.9 MSEK Higher expenses for payout of sales commissions related to
Slide 8: Improved cost efficiency
Improved cost efficiency Opex R12 (MSEK) • Annualized operating 300,0 expenses decreased by 31 250,0 242 257 259 243 MSEK since the peak of 259 235 229 228 216 MSEK in Q3’24. 205 200,0 195 • Continuous Q/Q reduction for three consecutive quarters. 150,0 • Reflects stronger cost control 100,0 measure
Slide 9: Long-term improved EBIT - soft performance in the quarter due to weaker revenue
Long-term improved EBIT - soft performance in the quarter due to weaker revenue Rolling 12 months EBIT Q2’25: 90,0 18% 8.4 (18.1) MSEK 80,0 16% Adjusted for unrealized fx 70,0 14% 9.3 (19.1) MSEK 60,0 12% 50,0 10% 40,0 8% EBIT margin Q2’25: 30,0 6% 8 (14) % 20,0 4% Adjusted for unrealized fx 10,0 2%
Slide 10: Improved cash flow Y/Y and a strong balance sheet
Improved cash flow Y/Y and a strong balance sheet Total cash flow by quarter (MSEK) Cash balance decreased with 3 MSEK from 161 MSEK 60,0 at end of Q1 to 158 MSEK end of Q2. 40,0 Operating cash flow was 0.5 (-2.5) MSEK and cash 20,0 flow from working capital was -7.9 (-26.5) MSEK. 0,0 Main reson beh
Slide 11: Summary & looking ahead
Summary & looking ahead Cecilia de Leeuw, CEO
Slide 12: Progress on our strategy in Q2
Progress on our strategy in Q2 Grow Sales & World-leading Untapped Market Steering Towards Market Reach Globally Products Potential Financial Targets Revenue and operating income 2023-2025(RTM), MSEK • Strengthen position by • Patient-centric and user- • SGRT (Surface Guided 600,0 20% growing in pri
Slide 13: Q&A
Q&A Cecilia de Leeuw Linda Frölén CEO CFO
Slide 14: Slide 14